Sopharma's sales up by 6% last year
This article was originally published in Scrip
Executive Summary
Unconsolidated sales of Sopharma, the second-largest pharmaceutical company in Bulgaria, increased by almost 6% to Lev169.9 million ($113.4 million) last year. Its net profit was affected by growing labour and raw material costs and fell by 30% to Lev19.2 million.